Global Health, which operates hospitals under the Medanta brand, posted its strongest-ever annual and quarterly financial performance for FY2026, driven by surging patient volumes, higher realizations and aggressive expansion across North and East India.

 

The hospital chain reported consolidated total income of Rs. 45,089 million for the financial year ended March 31, 2026, marking a sharp 19.6% year-on-year jump. EBITDA excluding the newly launched Noida facility rose 18.6% to Rs. 11,343 million, with margins holding firm at 25.7%.

 

Profit after tax climbed 15.1% year-on-year to Rs. 5,541 million, while the company’s board recommended a final dividend of 25% on the face value of Rs. 2 per share, translating to Rs. 0.50 per share.

 

The healthcare major also delivered its highest-ever quarterly revenue and operating profit in the January-March quarter. Q4 FY26 total income surged 25.3% year-on-year to Rs. 11,958 million, while EBITDA excluding Noida jumped 27% to Rs. 3,142 million.

 

The company’s aggressive expansion strategy significantly boosted capacity during the year, with Medanta adding 623 beds across its network — including 382 beds in Noida, 131 in Patna and a newly commissioned 110-bed hospital in Ranchi. Total bed capacity rose 20.5% year-on-year.

 

Medanta’s much-anticipated Noida hospital, formally inaugurated in November 2025, is now fully operational with 382 beds, including 98 ICU beds and 14 operating theatres. While the facility posted revenue of Rs. 906 million in FY26, it reported an EBITDA loss of Rs. 783 million as operations scaled up. However, quarterly losses narrowed, signaling improving momentum.

 

Patient traffic remained robust throughout the year. In-patient volumes rose 16% year-on-year, while out-patient volumes climbed 18.7%. Average revenue per occupied bed (ARPOB) increased 6.1% to Rs. 66,550, supported by a richer case mix and improved average length of stay.

 

The company’s developing hospitals excluding Noida emerged as a major growth engine, posting revenue growth of 29.2% year-on-year to Rs. 14,130 million. EBITDA from these facilities rose 35.2% to Rs. 4,447 million, with margins improving to 31.5%.

 

International business also saw strong traction, with revenue from overseas patients rising 33.2% year-on-year to Rs. 2,780 million. Meanwhile, Medanta’s OPD pharmacy business continued its rapid expansion, recording 30.4% growth to Rs. 1,826 million.

 

In the fourth quarter alone, in-patient numbers jumped 23% and out-patient visits rose 27.5% year-on-year, underscoring sustained demand momentum across the network.

 

Commenting on the performance, Pankaj Sahni, Group CEO and Director said: “FY2026 marked another year of strong execution for Medanta, with robust operational and financial performance across the network. Growth was driven by higher patient volumes, improved realizations, and consistent delivery across our hospitals.

 

"During the year, we successfully operationalized our 550-bed Noida hospital, which achieved NABH accreditation within the first six months, underscoring the strength of our institutional systems and clinical protocols. 

 

"The facility is now fully operational, supported by 200+ clinicians, 382 beds, 14 operating theatres, and advanced medical technologies. The ramp-up is progressing well and is increasingly reflected in our financial performance.

 

"Reinforcing our commitment to quality, our Lucknow hospital received JCI accreditation, becoming the first hospital in Uttar Pradesh to earn this distinction. Medanta Gurugram was also recognized by Newsweek as India’s Best Hospital and for the seventh consecutive year is ranked among the world’s top 150 hospitals."

 

Medanta expanded its bed capacity by 20% during the year. 

 

"We expect to add ~500 beds across existing hospitals over the next 12 months and ~2,700 beds through five greenfield projects over the next 3–4 years. Backed by a strong balance sheet and deep clinical expertise, we remain focused on strengthening our network through a disciplined and calibrated approach to expansion, anchored in quality," he added.